Alexion Pharmaceuticals’ flagship drug has made a strong case it can treat yet another rare disease, and the company is now mapping out plans to file for approval in the U.S. and other regions.
The Boston company released preliminary Phase 3 data for eculizumab (Soliris) as a treatment for neuromyelitis optica spectrum disorder (NMOSD), a central nervous system disorder that has no FDA-approved treatment. The Alexion antibody drug is already approved to treat two ultra-rare blood diseases: paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemoyltic uremic syndrome (aHUS). Investors welcomed the prospect of adding another disease to a product that is already… Read more »
UNDERWRITERS AND PARTNERS